← Map/THREAD · CELL-THERAPY
Cell Therapy (CAR-T / MSC)
The frontier, mostly preclinical for AS, but moving fast in adjacent autoimmune conditions.
Why this is a thread
This is the frontier of AS treatment, and it's mostly still preclinical. Two ideas matter most. Mesenchymal stem cells (MSCs) appear to push macrophages from the inflammatory M1 state toward the repair-mode M2 state, a direct way to address the macrophage problem at the centre of AS. CD19 CAR-T cell therapy, originally developed for cancer, has achieved drug-free remission in patients with severe lupus and scleroderma. That's a meaningful proof that re-engineering the immune system can reset autoimmune disease. Cell therapy isn't a standard AS treatment yet, but the science is moving fast, and the papers here track where that frontier is heading.
3 papers on the board
Single-cell profiling reveals senescent bone marrow mesenchymal stem cell subpopulations driving pathological ossification in ankylosing spondylitis.
Rheumatology (Oxford, England)
Single-cell analysis of bone marrow stem cells from people with ankylosing spondylitis found a worn-out, senescent group of cells that dominated in those with advanced spinal fusion and churned out bone-forming signals. New bone in AS may come from exhausted stem cells rather than healthy ones, which points to a different kind of drug target than inflammation.
Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity
Frontiers in Immunology
Reviews mesenchymal stem cell and CAR-T cell therapy approaches for AS. MSC therapy shifts inflammatory M1 macrophages toward anti-inflammatory M2; CAR-T is still experimental for AS specifically. Current treatments fail to improve long-term prognosis, cell therapy is positioned as the next frontier.
Therapeutic potential of CAR-expressing mesenchymal stem cells in inflammatory and autoimmune diseases
International Journal of Molecular Sciences
CAR-engineered mesenchymal stem cells combine the inflammation-homing properties of MSCs with antigen-specific targeting from CAR-T technology. Preclinical efficacy across multiple disease models, scalability and manufacturing remain the barriers to clinical adoption.